UTILITY OF MUTANT P53
IN NON-HODGKIN'S LYMPHOMA (NHL) USING SINGLE STRAND CONFIRMATION
POLYMORPHISM (SSCP)
Mohamed Awad1,
Gamal El-Wehedy2, Hassan Abd El-Ghaffar1, Mohamed
Salama3 and Omar Abd EL-Aziz1
Clinical
Pathology Dept. (Hematology Unit), Mansoura Faculty of Medicine, Mansoura
University, Masnoura, Egypt
NHL is one of the
lymphoid neopalsms which are highly variable in morphology, clinical
behavior, responses to treatment, and pathogenesis. P53 is a tumor
suppressor gene located on short arm of chromosome 17 at 13.1 locus have
been implicated in the patholgeneis of a wide variety of human cancer,
among them NHL. The value of mutant P53 to the clinical behaviour in NHL
have controversy, this has been triggered us to conduct this study. This work
was conducted on 34 patients with NHL, [10 patients with low grade NHL (6
CLL and 4 follicular lymphoma), 11 patients with intermediate grade NHL (6
diffuse large cells and 5 diffuse mixed cells) and 13 patients with high
grade NHL (7 Burkitt's and 6 lymphoblastic lymphoma), beside 10 healthy
subjects as a control group]. The SSCP technique was used in this study and
mutant P53 baund was detected by poluargmel gel electrophoresis. From this
study we found that P53 mutations were present in high percentage of NHL
patients (61.8%), which are prone to have extranodal infiltration by
lymphoam cells, lower disease free survival, advanced clinical stage of the
disease stage IV (85.7%) and in those with high grade lymphoma (69.2%).
Mutations of exon 6 of P53 among classical hot spot exon5 through exon 8
have been found in high frequency (35.3%), and its mutation associated with
advanced stage of the disease stage IV (57.8%), B.M involvement (53%) and
GLN (37.1). The clinical utility of screening P53 mutation is now important
especially to those using drugs in trial to increase wild type of P53
(apoptotic) that decrease the antiapopotic arm of mutant P53.